Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer
10.3760/cma.j.cn112139-20200422-00318
- VernacularTitle:可切除胰腺癌新辅助治疗进展及争议
- Author:
Xueli BAI
1
;
Xiang LI
;
Tingbo LIANG
Author Information
1. 浙江大学医学院附属第一医院肝胆胰外科 浙江省重症胰腺疾病诊治技术研究中心 浙江省肝胆胰疾病临床医学研究中心 浙江省胰腺病研究重点实验室，杭州 310000
- Keywords:
Pancreatic neoplasms;
Combined modality therapy;
Neoadjuvant chemotherapy;
Neoadjuvant radiotherapy;
Fluid biopsy;
Radiomics
- From:
Chinese Journal of Surgery
2020;58(7):486-489
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant therapy has been proved beneficial in patients with non-metastatic pancreatic cancer and it has received unprecedented attention in past years. However, the clinical value of neoadjuvant therapy in resectable pancreatic cancer patients remains controversial.Although the NCCN guideline has recommended that resectable pancreatic cancer patients with high-risk factors should be given preoperative neoadjuvant therapy, there is no consensus on specific criteria, treatment options, treatment duration and timing of surgery.More high-level evidences are strongly required.Recently, the development of new technologies such as liquid biopsy and radiomics analysis for pancreatic cancer will also help to address some clinical problems.This article reviewed the developments and controversies in neoadjuvant therapy for resectable pancreatic cancer.
